Sort
48,018 grants matching “immunotherapy”
Effects of Complement on the Tumor Microenvironment in Lung Cancer
$402,938Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2021 · CA
Effects of Complement on the Tumor Microenvironment in Lung Cancer
$402,938Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2020 · CA
Oral Pathogens and Dendritic Cell Subsets
$402,915Christopher W Cutler · State University New York Stony Brook · R01 · FY2008 · DE
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma
$402,872Muhammed Murtaza · Translational Genomics Research Inst · R01 · FY2019 · CA
Mechanisms of cell regulation and transformation
$402,833Tarun M Kapoor · Rockefeller University · T32 · FY2010 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$402,824Robert M Prins · University Of California Los Angeles · P50 · FY2025 · CA
Targeting Lag-3 and PD -1 in Myeloid Cells of GBM
$402,791Michael Lim · Stanford University · R01 · FY2022 · NS
TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity
$402,753Melanie R Rutkowski · University Of Virginia · R01 · FY2023 · CA
Core B: Biostatistics and Bioinformatics
$402,710Ted Gooley · Fred Hutchinson Cancer Research Center · P01 · FY2019 · CA
T cell function in murine gammaherpesvirus infection
$402,709Edward John Usherwood · Dartmouth College · R56 · FY2012 · AI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension
$402,708Brian Barkley Graham · University Of California, San Francisco · R01 · FY2020 · HL
Using gene expression profiles to elucidate mechanisms of melanoma progression
$402,693Ashani Weeraratna · National Institute On Aging · Z01 · FY2008 · AG
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
$402,618Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma
$402,618Hikmat Al-Ahmadie · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma
$402,618Hikmat Al-Ahmadie · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia
$402,600Anthony Folawuyi Daniyan · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition
$402,548Andrea Facciabene · University Of Pennsylvania · R01 · FY2017 · CA
Molecular Mechanisms in Gastrointestinal Stromal Tumor
$402,500Ronald P Dematteo · University Of Pennsylvania · R01 · FY2018 · CA
Non-racemic metabolic biomaterials for HFpEF
$402,500Andrei Maiseyeu · Case Western Reserve University · R01 · FY2021 · HL
Innate Antiviral Signals for Cancer Immunotherapy
$402,500Matthias Gromeier · Duke University · R01 · FY2023 · NS
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions
$402,500E. Ashley Moseman · Duke University · R01 · FY2021 · NS
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease
$402,500Dianne M Perez · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · AG
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease
$402,500Dianne M Perez · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · AG
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions
$402,500E. Ashley Moseman · Duke University · R01 · FY2025 · NS
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease
$402,500Dianne M Perez · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · AG